Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Summary

The purpose of this study is to assess the efficacy and safety of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Timeline

Start

2019-04-19

Primary completion

2021-04-01

Completion

2021-12-31

Publications

• Liu J, He M, Jiang M, Zhou S, Zhang M, Li Y, Chen S, Cai R, Mo H, Lan B, Ma F, Xu B, Li Q. Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. BMC Cancer. 2024 Oct 18;24(1):1290. doi: 10.1186/s12885-024-13041-8.

Drugs

Indications